2025-2026 Regular Session • US Congress Legislature
SB1096: Preserve Access to Affordable Generics and Biosimilars Act
Legislative Summary
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Demographic Impact
Overall analysis of equity impact
80% Positive
High ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
3/24/2025
Read twice and referred to the Committee on the Judiciary.
Senate
4/3/2025
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Senate
4/10/2025
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Senate
4/10/2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
Senate
Status Information
Current Status
Introduced(3/24/2025)
Chamber
Senate
Sponsors
Democrat: 6
Republican: 3
Primary Sponsor
Amy Klobuchar
Democrat